Milestone: Creating Innovative Solutions Milestone Home
 
image thru microscope
Symposia Contact Home

CPSA Digest 2004

Integrated Approaches to Drug Discovery & Development: Turning Measurements to Medicine

CPSA Digest 2004

Day 1: Proceedings | Plenary
Day 2: Proceedings
Day 3: Proceedings

CPSA 2004 Sponsors

Past CPSA Digests
CPSA Digest 2000
CPSA Digest 2001
CPSA Digest 2002
CPSA Digest 2003


Proceedings

Day 3 - Thursday, October 21, 2004



Tissue Imaging – Localization of Drugs and Metabolites

Discussion Leader:Yunsheng Hsieh, Schering Plough Research Institute

The use of mass spectrometric techniques as an analytical tool has become standard in pharmaceutical research and development. Mass spectrometry is routinely applied throughout all phases of drug discovery and development, from the synthesis of new chemical entities (for structural characterization) to the analysis of lead compounds in clinical trials (for metabolite identification and pharmacokinetics). This session will discuss various MS-based imaging methodologies to provide useful information about the localization of a given target in biological tissues.

Mapping Small Molecules in Intact Tissue by Laser Microprobe Ion Trap Tandem Mass Spectrometry

Timothy Garrett and Richard Yost, University of Florida

Imaging Proteins in Tissues via MALDI Mass Spectrometry

Michelle L. Reyzer, Vanderbilt University

Imaging Mass Spectrometry for Probing the Brain

Stanislav Rubakhin, University of Illinois

Tissue Imaging Using MALDI Tandem Mass Spectrometry for Drug Candidates

Yunsheng Hsieh, Schering-Plough Research Institute



Biomarker Evaluation

Discussion Leaders: Bradley Ackermann, Eli Lilly and Company;
Sushmita M. Roy, SurroMed

This session will focus on strategies and techniques used in the difficult, yet essential, process of translating candidate markers into tools that truly guide pre-clinical and clinical pharmacology. The importance of cross-functional partnerships, emerging technologies, and iterative learning will be emphasized.

Quantitation of Peptides & Protein Biomarkers by Mass Spectrometry

Brad Guild, Millennium

Analysis of Small Molecule Biomarkers

Susan K. Ohorodnik, SFBC-Taylor Technologies

Establishing Pre-Clinical and Clinical PK/PD Relationships

Carl Garner, Eli Lilly and Company



Lunch/Roundtables – Compound Library Analysis and Profiling

Discussion Leaders: Dalin Nie, AstraZeneca
David Semin, Amgen

The success of drug discovery research relies upon the quality of the corporate compound library. As compound stability can be affected by many factors, it is important to assess the quality of the library over time. Advances in analytical technologies made it possible. The discussion will be focused on assessing the quality of compound library with analytical technology.



Emerging Technologies and Applications

Discussion Leader: David Wagner, GlaxoSmithKline

The last few decades has generated extraordinary technological advancements in medicine, science, transportation, engineering, and communication. These technologies have changed the way in which we live our personal lives as well as scientists’ ability to conduct research. New technologies are constantly being developed world wide in universities and companies, and speculating which ones will transform science is challenging. Several emerging areas of technology that should have a profound impact on the pharmaceutical industry will be discussed. These advances incorporate instrumentation, nanotechnology, and novel sample preparation. Each technology will be highlighted exemplifying the potential and promise for the pharmaceutical industry.

HPLC Chip Technology

Tom A. van de Goor, Agilent Technologies

Ion/Ion Methods for Peptide and Protein Sequence Analysis: Electron Transfer Dissociation and Beyond

Joshua J. Coon, John E.P. Syka, Jeffrey Shabanowitz, Donald F. Hunt, University of Virginia

Microwave-Enhanced Proteomic Applications – Rapid and Efficient Techniques for Protein Analysis

J. Doug Ferguson, E. Keller Barnhardt, CEM Corporation


Wrap Up

Co-Chairs: Steven A. Hofstadler, Ibis Therapeutics
Mark Sanders, Bristol-Myers Squibb



overview | training | workshops | consulting | symposia | contact | home